Federal Judge to Rule on RFK Jr.'s Vaccine Overhaul

Lawsuit challenges changes to vaccine guidance and advisory panel

Feb. 12, 2026 at 10:15am

A federal judge in Boston will hear arguments on February 13th regarding the Trump administration's overhaul of vaccine recommendations. The lawsuit was filed by the American Academy of Pediatrics and other health organizations against the Department of Health and Human Services, Health Secretary Robert F. Kennedy Jr., and other government officials over the changes.

Why it matters

The outcome of this case could have significant implications for the future of vaccine policy in the United States, as the Trump administration's changes were seen as controversial and a departure from established scientific consensus.

The details

The lawsuit challenges the administration's moves to alter vaccine guidance and reconstitute the vaccine advisory panel with members who have expressed skepticism about certain vaccines. Health organizations argue these changes could undermine public confidence in vaccination and lead to lower vaccination rates.

  • The hearing is scheduled for February 13, 2026.
  • The lawsuit was filed in response to the Trump administration's vaccine overhaul.

The players

U.S. District Judge Brian Murphy

The federal judge presiding over the case in Boston.

Department of Health and Human Services (HHS)

The federal agency being sued over the vaccine guidance changes.

Robert F. Kennedy Jr.

The Health Secretary who oversaw the vaccine policy changes under the Trump administration.

American Academy of Pediatrics

One of the health organizations that filed the lawsuit challenging the vaccine guidance changes.

Got photos? Submit your photos here. ›

What’s next

The judge is expected to rule on the case shortly after the February 13th hearing.

The takeaway

This lawsuit highlights the ongoing debate over vaccine policy and the role of government in setting public health guidelines. The judge's decision could shape the future of vaccination requirements and recommendations in the U.S.